William Blair and MaidStone Life Sciences Biotech Focus Conference

Day One

12th Annual Cancer Immunotherapy Conference

8:00 a.m.

Keynote I: Physicians View of the Challenges and Unmet Needs in Cell Therapies

Matthew Frigault, M.D.

Administrative Director, Cellular Therapy Service

Assistant Professor of Medicine, Harvard Medical School

8:30 a.m.

Q&A

8:45 a.m.

Break

8:55 a.m.

Panel I: Preparing for Launch: Navigating the Regulatory Landscape and Operationalizing Cell Therapies

(Raj moderating)

 

Participating Companies:

Allogene Therapeutics, Inc. (ALLO)

Eric Schmidt, Ph.D.

CFO

 

Autolus Therapeutics, Ltd. (AUTL)

Christian Itin, Ph.D.

CEO

 

Arcellx, Inc. (ACLX)

Rami Elghandour

CEO

 

Obsidian Therapeutics (private)

Paul Wotton, Ph.D.

CEO

 

Affini-T Therapeutics, Inc. (private)

Jak Knowles, M.D.

Co-founder, President & CEO

 

10:15 a.m.

Break

10:25 a.m.

Keynote II: Engineering T-Cells for Enhanced Immunotherapy of Solid Tumors

Michael C. Milone, M.D., Ph.D.

Assistant Professor of Pathology and Laboratory Medicine at the Hospital of University of Pennsylvania

Associate Director, Toxicology Laboratory

University of Pennsylvania Perelman School of Medicine

 

10:55 a.m.

Q&A

11:05 a.m.

Break

 

11:15 a.m.

 

Panel II: Off The shelf: Next-Generation Allogeneic Cell Therapies

(Sami Moderating)

 

Participating Companies:

Nkarta, Inc. (NKTX)

Paul Hastings

CEO

 

Poseida Therapeutics, Inc. (PSTX)

Mark Gergen

CEO

 

Wugen, Inc. (private)

Dan Kemp, Ph.D.

CEO

 

Century Therapeutics, Inc. (IPSC)

Lalo Flores, Ph.D.

CEO


Beam Therapeutics, Inc. (BEAM)

John Evans

CEO

 

12:15 p.m.

Lunch

1:00 p.m.

.

Keynote III: Multispecific Protein Therapies: Where weve Been and Where Were Going?

Patrick Baeuerle, Ph.D.,

Co-founder and Acting Chief Scientific Officer

Cullinan Oncology

Executive Partner, MPM Capital

1:30 p.m.

Q&A

1:40 p.m.

Break

1:50 p.m.

 

Panel III: Moving Beyond Monoclonals: The Potential of Multispecific Therapies

(Phipps moderating)

 

Participating Companies:

Immunocore Holdings Plc (IMCR)

Bahija Jallal, Ph.D.

CEO

 

Merus N.V. (MRUS)

Bill Lundberg, M.D.

CEO, Principal Financial Officer

 

Pieris Pharmaceuticals, Inc. (PIRS)

Steve Yoder

CEO

 

TRIO Pharmaceuticals, Inc. (private)

Reiner Laus, M.D.

CEO and Co-founder

3:10 p.m.

Break

3:20 p.m.

Keynote IV: Clinical Trial Considerations for Biology Informed Immuno-Oncology Drug Development

TBD

3:50 p.m.

Q&A

4:00 p.m.

Break

4:10 p.m.

Panel IV: Developing Therapies for the Next Immuno-Oncology Targets

(Phipps moderating)

 

Participating Companies:

 

Agenus, Inc. (AGEN)

Steven ODay, M.D.

CMO

 

Codiak BioSciences, Inc. (CDAK)

Doug Williams, Ph.D.,

CEO

 

Tempest Therapeutics, Inc. (TPST)

Tom Dubensky, Ph.D.,

President

 

Hibercell, Inc. (private)

Alan Rigby, Ph.D.
President & CEO

5:20 p.m.

Closing Remarks

 

 


 

Day Two

Key Topics in Biotech

 

 

Panel Discussions

 

9:00 a.m.

Panel 1: Next Generation Small Molecules in Oncology

 

Ikena Oncology, Inc. (IKNA)

Mark Manfredi, Ph.D.

President & CEO

 

Kinnate Biopharma, Inc. (KNTE)

Nima Farzan

CEO

 

Immuneering Corp. (IMRX)

Benjamin Zeskind, Ph.D.

Co-Founder, President and CEO

 

 

 

 

9:45 a.m.

Break

 

10:00 a.m.

Panel 2: AAV Gene Therapy: Delivery and Beyond

 

Taysha Gene Therapies, Inc. (TSHA)

RA Session II

President, Founder & CEO

 

Renovacor, Inc. (RCOR)

Magdalene Cook, Ph.D.

President & Chief Executive Officer

 

 

 

10:45 a.m.

Break

 

11:00 a.m.

Panel 3: Developing Therapies Against Novel Targets in Autoimmune Diseases

 

Kezar Life Sciences, Inc (KZR)

Noreen Roth Henig, M.D.,

CMO

 

Aclaris Therapeutics, Inc. (ACRS)

Neal Walker, D.O.

President & CEO

 

Nimbus Therapeutics (Private)

Jeb Keiper

Chief Executive Officer

 

Ventus Therapeutics, Inc. (Private)

Michael Crackower, Ph.D.,

CSO

 

 

 

11:45 a.m.

Break

 

12:00 p.m.

Panel 4: Unmet Needs and Novel Therapies in Neuropsychiatry

 

Axsome Therapeutics, Inc. (AXSM)

Herriot Tabuteau, MD

CEO

 

VistaGen Therapeutics, Inc. (VTGN)

Shawn Singh, J.D.

CEO

 

Bionomics Limited (BNOX)

Errol De Souza, Ph.D.

Executive Chairman

 

 

12:45 p.m.

Break

 

1:00 p.m.

Panel 5: There And Back Again, Dawn Of A New Era in Radiopharmaceuticals

 

Point Biopharma Global Inc.

Joe McCann, Ph.D.

President & CEO

 

Fusion Pharmaceuticals Inc.

John Valliant, Ph.D.

Founder & CEO

 

Aktis Oncology, Inc.

Matthew Roden, Ph.D.

President & CEO

 

Telix Pharmaceuticals Ltd.

Chris Behrenbruch, DPhil, J.D., MBA

Group Managing Director and CEO

 

1:45 p.m.

Break

 

2:00 p.m.

Panel 6: Novel Modalities and Delivery for RNA-Targeted Therapeutics

 

Ionis Pharmaceuticals, Inc. (IONS)

Brett Monia, Ph.D.

CEO

 

Silence Therapeutics, plc (SLN)

Craig Tooman

CEO

 

ReCode Therapeutics, Inc.

David Lockhart, Ph.D.

President and CSO

 

Locanabio, Inc.

Jim Burns, Ph.D.

CEO

 

 

2:45 p.m.

Break

 

3:00 p.m.

Panel 7: Developing Genomic Medicines

 

Generation Bio Co.

Geoff McDonough, M.D.

President and CEO

 

Arbor Biotechnologies

Devyn Smith, Ph.D.

CEO

 

Design Therapeutics, Inc.

Joo Siffert, M.D.

President and CEO

 

Verve Therapeutics, Inc.

Sekar Kathiresan, M.D.

Co-founder and CEO

 

Metagenomi, Inc.

Simon Harnest

Chief Investment Officer and SVP of Strategy

 

 

 

 

 

 

 


 

Virtual Fireside Chats

Aileron Therapeutics, Inc.

Albireo Pharma, Inc.

Alector, Inc. (invited, not confirmed)

Aravive, Inc.

Atea Pharmaceuticals, Inc.

Bellus Health, Inc.

Biohaven Pharmaceutical Holding Co. Ltd

Brickell Biotech, Inc.

Caraway Therapeutics, Inc.

Cardiff Oncology, Inc.

Chinook Therapeutics, Inc.

CRISPR Therapeutics AG

CytoImmune Therapeutics, Inc.

Entrada Therapeutics, Inc.

Elucida Oncology, Inc

Exelixis, Inc.

Geneius Biotechnology, Inc.

Icosavax, Inc.

ImmunoGen, Inc.

Inventiva S.A.

KAHR Bio

Krystal Biotech, Inc.

PhaseBio Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc.

UniQure N.V.

Vaccitech plc

Vedanta Biosciences, Inc.

Viking Therapeutics, Inc.

Viridian Therapeutics, Inc. (do not show as attending company yet)

Xenon Pharmaceuticals, Inc.